Abbvie Inc.
A global biopharmaceutical company, AbbVie develops and sells medicines for immune, nerve, and cancer conditions — brands include Skyrizi, Rinvoq, Humira, Botox, and Imbruvica — as well as cosmetic treatments like Botox Cosmetic and the Juvederm line. It was born in 2013 when Abbott Laboratories split, spinning off its drug business into a fresh company. Fun fact: the name blends "Abb" (from Abbott) with "Vie," echoing the Latin word for "life," and insiders noted it conveniently rhymes with "R&D."
Granted 36.8K
Granted 82.4K
Granted 1.1K
Granted 53.7K
Granted 29.1K
Granted 1.1K
Granted 18.1K
Granted 1.1K
Granted 48.8K
Granted 1.1K
Granted 1.1K
Granted 1.1K
Granted 1.1K
Granted 55.9K · Sold 41.0K
Granted 1.1K
Granted 2.5K
Granted 1.1K
Granted 1.1K
Granted 1.1K
Granted 6.1K · Sold 5.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICER · 5 transactions | -9.6% | 204.4K | 36.8K | — | — |
| Michael Robert A.CHAIRMAN OF THE BOARD AND CEO, Director · 5 transactions | +34.6% | 178.7K | 82.4K | — | — |
| Freyman Thomas CDirector · 1 transaction | +0.8% | 133.8K | 1.1K | — | — |
| Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER · 5 transactions | -3.6% | 84.5K | 53.7K | — | — |
| Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER · 5 transactions | +9% | 74.4K | 29.1K | — | — |
| Rapp Edward JDirector · 1 transaction | +25.7% | 56.4K | 1.1K | — | — |
| Thakkar RoopalEVP, R&D and CSO · 5 transactions | — | 55.4K | 18.1K | — | — |
| Austin Roxanne SDirector · 1 transaction | +2.9% | 39.6K | 1.1K | — | — |
| Reents Scott TEVP, CHIEF FINANCIAL OFFICER · 5 transactions | +234.9% | 38.8K | 48.8K | — | — |
| Waddell Frederick HDirector · 1 transaction | +3.9% | 30.1K | 1.1K | — | — |
| Burnside William H.L.Director · 1 transaction | +4.1% | 28.1K | 1.1K | — | — |
| Hart Brett JDirector · 1 transaction | +5.7% | 20.6K | 1.1K | — | — |
| Meyer Melody BDirector · 1 transaction | +6.8% | 17.6K | 1.1K | — | — |
| Siatis Perry CEVP, GC AND SECRETARY · 12 transactions | +17.9% | 17.5K | 55.9K | — | 41.0K |
| Roberts Rebecca BDirector · 1 transaction | +8.1% | 14.8K | 1.1K | — | — |
| Crum Demetris DEVP, CHIEF HR OFFICER · 3 transactions | +12.3% | 7.9K | 2.5K | — | — |
| Falk Thomas JDirector · 1 transaction | +26.6% | 5.3K | 1.1K | — | — |
| Davis Jennifer L.Director · 1 transaction | +44.3% | 3.6K | 1.1K | — | — |
| Quaggin Susan EDirector · 1 transaction | +44.3% | 3.6K | 1.1K | — | — |
| Purdue David RyanSVP, Controller · 6 transactions | -78.4% | 1.1K | 6.1K | — | 5.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -46.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.